Search

Your search keyword '"Staropoli, Nicoletta"' showing total 164 results
Start Over Author "Staropoli, Nicoletta"
164 results on '"Staropoli, Nicoletta"'

2. Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study

Author

Tassone, Pierfrancesco, Di Martino, Maria Teresa, Arbitrio, Mariamena, Fiorillo, Lucia, Staropoli, Nicoletta, Ciliberto, Domenico, Cordua, Alessia, Scionti, Francesca, Bertucci, Bernardo, Salvino, Angela, Lopreiato, Mariangela, Thunarf, Fredrik, Cuomo, Onofrio, Zito, Maria Cristina, De Fina, Maria Rosanna, Brescia, Amelia, Gualtieri, Simona, Riillo, Caterina, Manti, Francesco, Caracciolo, Daniele, Barbieri, Vito, Di Paola, Eugenio Donato, Di Francesco, Adele Emanuela, and Tagliaferri, Pierosandro

Published
2023
Full Text
View/download PDF

3. A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer

Author

Riillo, Caterina, Polerà, Nicoletta, Di Martino, Maria Teresa, Juli, Giada, Hokanson, Craig A., Odineca, Tatjana, Signorelli, Stefania, Grillone, Katia, Ascrizzi, Serena, Mancuso, Antonia, Staropoli, Nicoletta, Caparello, Basilio, Cerra, Maria, Nisticò, Giuseppe, Tagliaferri, Pierosandro, Crea, Roberto, Caracciolo, Daniele, and Tassone, Pierfrancesco

Published
2023
Full Text
View/download PDF

4. Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience

Author

Staropoli, Nicoletta, Scionti, Francesca, Farenza, Valentina, Falcone, Federica, Luciano, Francesco, Renne, Maria, Di Martino, Maria Teresa, Ciliberto, Domenico, Tedesco, Ludovica, Crispino, Antonella, Labanca, Caterina, Cucè, Maria, Esposito, Stefania, Agapito, Giuseppe, Cannataro, Mario, Tassone, Pierfrancesco, Tagliaferri, Pierosandro, and Arbitrio, Mariamena

Published
2024
Full Text
View/download PDF

5. The impact of PARP inhibitors in the whole scenario of ovarian cancer management: A systematic review and network meta-analysis

Author

Staropoli, Nicoletta, Ciliberto, Domenico, Luciano, Francesco, Napoli, Cristina, Costa, Martina, Rossini, Giacomo, Arbitrio, Mariamena, Labanca, Caterina, Riillo, Caterina, Del Giudice, Teresa, Crispino, Antonella, Salvino, Angela, Galvano, Antonio, Russo, Antonio, Tassone, Pierfrancesco, and Tagliaferri, Pierosandro

Published
2024
Full Text
View/download PDF

8. Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin

Author

Caracciolo, Daniele, Juli, Giada, Riillo, Caterina, Coricello, Adriana, Vasile, Francesca, Pollastri, Sara, Rocca, Roberta, Scionti, Francesca, Polerà, Nicoletta, Grillone, Katia, Arbitrio, Mariamena, Staropoli, Nicoletta, Caparello, Basilio, Britti, Domenico, Loprete, Giovanni, Costa, Giosuè, Di Martino, Maria Teresa, Alcaro, Stefano, Tagliaferri, Pierosandro, and Tassone, Pierfrancesco

Published
2022
Full Text
View/download PDF

10. Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis

Author

Caputo, Roberta, primary, Buono, Giuseppe, additional, Piezzo, Michela, additional, Martinelli, Claudia, additional, Cianniello, Daniela, additional, Rizzo, Alessandro, additional, Pantano, Francesco, additional, Staropoli, Nicoletta, additional, Cangiano, Rodolfo, additional, Turano, Salvatore, additional, Paris, Ida, additional, Nuzzo, Francesco, additional, Fabi, Alessandra, additional, and De Laurentiis, Michelino, additional

Published
2024
Full Text
View/download PDF

12. UMG1/CD3ε‐bispecific T‐cell engager redirects T‐cell cytotoxicity against diffuse large B‐cell lymphoma

Author

Caracciolo, Daniele, primary, Polerà, Nicoletta, additional, Belmonte, Beatrice, additional, Conforti, Francesco, additional, Signorelli, Stefania, additional, Gulino, Alessandro, additional, Staropoli, Nicoletta, additional, Tuccillo, Franca Maria, additional, Bonelli, Patrizia, additional, Juli, Giada, additional, Grillone, Katia, additional, Ascrizzi, Serena, additional, Cirillo, Maria, additional, Migale, Leonardo, additional, Ballerini, Andrea, additional, Pelizon, Cristina, additional, Di Martino, Maria Teresa, additional, Tagliaferri, Pierosandro, additional, Riillo, Caterina, additional, and Tassone, Pierfrancesco, additional

Published
2023
Full Text
View/download PDF

15. Genetic biomarkers for sorafenib response in patients with hepatocellular carcinoma

Author

Augello, Giuseppa, primary, Arbitrio, Mariamena, additional, Giannitrapani, Lydia, additional, Scionti, Francesca, additional, Ciliberto, Domenico, additional, Staropoli, Nicoletta, additional, Agapito, Giuseppe, additional, Tassone, Pierfrancesco, additional, Tagliaferri, Pierosandro, additional, Soresi, Maurizio, additional, Seidita, Aurelio, additional, Affronti, Marco, additional, Bertino, Gaetano, additional, Russello, Maurizio, additional, Di Gaudio, Francesca, additional, Ciriminna, Rosaria, additional, Spinnato, Francesca, additional, Verderame, Francesco, additional, and Cervello, Melchiorre, additional

Published
2023
Full Text
View/download PDF

16. Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma.

Author

Giannitrapani, Lydia, Di Gaudio, Francesca, Cervello, Melchiorre, Scionti, Francesca, Ciliberto, Domenico, Staropoli, Nicoletta, Agapito, Giuseppe, Cannataro, Mario, Tassone, Pierfrancesco, Tagliaferri, Pierosandro, Seidita, Aurelio, Soresi, Maurizio, Affronti, Marco, Bertino, Gaetano, Russello, Maurizio, Ciriminna, Rosaria, Lino, Claudia, Spinnato, Francesca, Verderame, Francesco, and Augello, Giuseppa

Subjects
GENETIC risk score, HEPATOCELLULAR carcinoma, SORAFENIB, DRUG absorption, BIOMARKERS
Abstract

The identification of biomarkers for predicting inter-individual sorafenib response variability could allow hepatocellular carcinoma (HCC) patient stratification. SNPs in angiogenesis- and drug absorption, distribution, metabolism, and excretion (ADME)-related genes were evaluated to identify new potential predictive biomarkers of sorafenib response in HCC patients. Five known SNPs in angiogenesis-related genes, including VEGF-A, VEGF-C, HIF-1a, ANGPT2, and NOS3, were investigated in 34 HCC patients (9 sorafenib responders and 25 non-responders). A subgroup of 23 patients was genotyped for SNPs in ADME genes. A machine learning classifier method was used to discover classification rules for our dataset. We found that only the VEGF-A (rs2010963) C allele and CC genotype were significantly associated with sorafenib response. ADME-related gene analysis identified 10 polymorphic variants in ADH1A (rs6811453), ADH6 (rs10008281), SULT1A2/CCDC101 (rs11401), CYP26A1 (rs7905939), DPYD (rs2297595 and rs1801265), FMO2 (rs2020863), and SLC22A14 (rs149738, rs171248, and rs183574) significantly associated with sorafenib response. We have identified a genetic signature of predictive response that could permit non-responder/responder patient stratification. Angiogenesis- and ADME-related genes correlation was confirmed by cumulative genetic risk score and network and pathway enrichment analysis. Our findings provide a proof of concept that needs further validation in follow-up studies for HCC patient stratification for sorafenib prescription. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. UMG1/CD3ε‐bispecific T‐cell engager redirects T‐cell cytotoxicity against diffuse large B‐cell lymphoma.

Author

Caracciolo, Daniele, Polerà, Nicoletta, Belmonte, Beatrice, Conforti, Francesco, Signorelli, Stefania, Gulino, Alessandro, Staropoli, Nicoletta, Tuccillo, Franca Maria, Bonelli, Patrizia, Juli, Giada, Grillone, Katia, Ascrizzi, Serena, Cirillo, Maria, Migale, Leonardo, Ballerini, Andrea, Pelizon, Cristina, Di Martino, Maria Teresa, Tagliaferri, Pierosandro, Riillo, Caterina, and Tassone, Pierfrancesco

Subjects
DIFFUSE large B-cell lymphomas, CYTOTOXINS, T cells, BONE cells
Abstract

Summary: UMG1 is a unique epitope of CD43, not expressed by normal cells and tissues of haematopoietic and non‐haematopoietic origin, except thymocytes and a minority (<5%) of peripheral blood T lymphocytes. By immunohistochemistry analysis of tissue microarray and pathology slides, we found high UMG1 expression in 20%–24% of diffuse large B‐cell lymphomas (DLBCLs), including highly aggressive BCL2high and CD20low cases. UMG1 membrane expression was also found in DLBCL bone marrow‐infiltrating cells and established cell lines. Targeting UMG1 with a novel asymmetric UMG1/CD3ε‐bispecific T‐cell engager (BTCE) induced redirected cytotoxicity against DLBCL cells and was synergistic with lenalidomide. We conclude that UMG1/CD3ε‐BTCE is a promising therapeutic for DLBCLs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Prevalence of Non-erosive Esophageal Phenotypes in Children: A European Multicenter Study

Author

Blasi, Elisa, primary, Stefanelli, Ettore, additional, Tambucci, Renato, additional, Salvatore, Silvia, additional, Angelis, Paola De, additional, Quitadamo, Paolo, additional, Pacchiarotti, Claudia, additional, Nardo, Giovanni Di, additional, Crocco, Fanj, additional, Felici, Enrico, additional, Giorgio, Valentina, additional, Staropoli, Nicoletta, additional, Sestito, Simona, additional, Saliakellis, Efstratios, additional, Borrelli, Osvaldo, additional, and Pensabene, Licia, additional

Published
2023
Full Text
View/download PDF

19. The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas

Author

Polerà, Nicoletta, primary, Mancuso, Antonia, additional, Riillo, Caterina, additional, Caracciolo, Daniele, additional, Signorelli, Stefania, additional, Grillone, Katia, additional, Ascrizzi, Serena, additional, Hokanson, Craig A., additional, Conforti, Francesco, additional, Staropoli, Nicoletta, additional, Gervasi, Luigia, additional, Di Martino, Maria Teresa, additional, Arbitrio, Mariamena, additional, Nisticò, Giuseppe, additional, Crea, Roberto, additional, Tagliaferri, Pierosandro, additional, Juli, Giada, additional, and Tassone, Pierfrancesco, additional

Published
2023
Full Text
View/download PDF

21. Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma

Author

Cucè, Maria, Gallo Cantafio, Maria Eugenia, Siciliano, Maria Anna, Riillo, Caterina, Caracciolo, Daniele, Scionti, Francesca, Staropoli, Nicoletta, Zuccalà, Valeria, Maltese, Lorenza, Di Vito, Anna, Grillone, Katia, Barbieri, Vito, Arbitrio, Mariamena, Di Martino, Maria Teresa, Rossi, Marco, Amodio, Nicola, Tagliaferri, Pierosandro, Tassone, Pierfrancesco, and Botta, Cirino

Published
2019
Full Text
View/download PDF

22. Additional file 1 of Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study

Author

Tassone, Pierfrancesco, Di Martino, Maria Teresa, Arbitrio, Mariamena, Fiorillo, Lucia, Staropoli, Nicoletta, Ciliberto, Domenico, Cordua, Alessia, Scionti, Francesca, Bertucci, Bernardo, Salvino, Angela, Lopreiato, Mariangela, Thunarf, Fredrik, Cuomo, Onofrio, Zito, Maria Cristina, De Fina, Maria Rosanna, Brescia, Amelia, Gualtieri, Simona, Riillo, Caterina, Manti, Francesco, Caracciolo, Daniele, Barbieri, Vito, Di Paola, Eugenio Donato, Di Francesco, Adele Emanuela, and Tagliaferri, Pierosandro

Abstract

Additional file 1. Supplementary information: Systematic review of anti-miRNA therapeutics of human cancer. Fig S1: Dose-escalation phase I treatments according to a 3+3 design and Fibonacci dose-escalation protocol. Table S1: Patients, demography, pathology and stage. Table S2: Previous treatments. Table S3: AE distribution in terms of CTCAE System Organ Class. Table S4: Adverse events. Safety analysis set. Table S5: Analysis of LNA-i-miR-221 in urine, 0.5 mg/kg dose. A) Treatment Day 1, B) Treatment Day 4. Table S6: Mean plasma PK parameters for each LNA-i-miR-211 dose. Access Link to the Clinical Trial Protocol (Version 3.0).

Published
2023
Full Text
View/download PDF

23. Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Advanced Breast Cancer Patients: An Italian Managed Access Program

Author

Staropoli, Nicoletta, primary, Geuna, Elena, additional, Rinaldi, Gaetana, additional, Bisagni, Giancarlo, additional, Scotti, Vieri, additional, Faggioni, Giovanni, additional, Vannini, Laura, additional, Arcara, Carlo, additional, Moretti, Gabriella, additional, Gunnellini, Marco, additional, Coltelli, Luigi, additional, Verderame, Francesco, additional, Livi, Lorenzo, additional, Sanna, Giuseppina, additional, Grasso, Donatella, additional, Abbinante, Giulia, additional, and Ragni, Francesca, additional

Published
2022
Full Text
View/download PDF

24. Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity.

Author

Staropoli, Nicoletta, Salvino, Angela, Falcone, Federica, Farenza, Valentina, Costa, Martina, Rossini, Giacomo, Manti, Francesco, Crispino, Antonella, Riillo, Caterina, Ciliberto, Domenico, Arbitrio, Mariamena, Tassone, Pierfrancesco, and Tagliaferri, Pierosandro

Subjects
ENDOMETRIAL cancer, LUNGS, LITERATURE reviews, NEOVASCULARIZATION inhibitors, PEMBROLIZUMAB
Abstract

Background: The optimal strategy for the treatment of recurrent and/or advanced endometrial cancer is still undefined. Recently, despite the lack of any predictive biomarker, the combination of pembrolizumab with lenvatinib has improved survival outcomes. We here report the long-term management of lung toxicity in a patient with endometrial cancer, and we critically review the current therapeutic options for this disease. Results: A patient with heavily pretreated endometrial cancer took pembrolizumab plus lenvatinib for 1 year, achieving a persistent partial response with a time to treatment failure of 18 months, despite relevant lung toxicity that did not affect the remarkable overall clinical benefit. A systematic review of this combination underlines the efficacy outcome despite toxicity. Interestingly, the literature review on lung toxicity suggested the role of antiangiogenetic agents in the pathogenesis of lung cavitation, probably related to direct treatment activity, and disclosed a potential radiological sign predictive of the activity of anti-angiogenetic agents. Conclusion: We underline the efficacy of pembrolizumab plus lenvatinib in the current treatment landscape of endometrial cancer, underscoring the relevance of a correct management of toxicity. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

25. A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics

Author

Staropoli, Nicoletta, primary, Arbitrio, Mariamena, additional, Salvino, Angela, additional, Scionti, Francesca, additional, Ciliberto, Domenico, additional, Ingargiola, Rossana, additional, Labanca, Caterina, additional, Agapito, Giuseppe, additional, Iuliano, Eleonora, additional, Barbieri, Vito, additional, Cucè, Maria, additional, Zuccalà, Valeria, additional, Cannataro, Mario, additional, Tassone, Pierfrancesco, additional, and Tagliaferri, Pierosandro, additional

Published
2022
Full Text
View/download PDF

26. Frontline therapy CLL without 17p del/p53 aberrations: systematic review and Bayesian network meta-analysis

Author

Caridà, Giulio, primary, Pelaia, Giulia, additional, Ciliberto, Domenico, additional, Staropoli, Nicoletta, additional, Siciliano, Maria Anna, additional, Calandruccio, Natale Daniele, additional, Caracciolo, Daniele, additional, Riillo, Caterina, additional, Toscano, Rosa, additional, Tagliaferri, Pierosandro, additional, Tassone, Pierfrancesco, additional, and Rossi, Marco, additional

Published
2022
Full Text
View/download PDF

27. Additional file 2 of Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin

Author

Caracciolo, Daniele, Juli, Giada, Riillo, Caterina, Coricello, Adriana, Vasile, Francesca, Pollastri, Sara, Rocca, Roberta, Scionti, Francesca, Polerà, Nicoletta, Grillone, Katia, Arbitrio, Mariamena, Staropoli, Nicoletta, Caparello, Basilio, Britti, Domenico, Loprete, Giovanni, Costa, Giosuè, Di Martino, Maria Teresa, Alcaro, Stefano, Tagliaferri, Pierosandro, and Tassone, Pierfrancesco

Abstract

Additional file 2: Supplementary Methods

Published
2022
Full Text
View/download PDF

28. Additional file 1 of Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin

Author

Caracciolo, Daniele, Juli, Giada, Riillo, Caterina, Coricello, Adriana, Vasile, Francesca, Pollastri, Sara, Rocca, Roberta, Scionti, Francesca, Polerà, Nicoletta, Grillone, Katia, Arbitrio, Mariamena, Staropoli, Nicoletta, Caparello, Basilio, Britti, Domenico, Loprete, Giovanni, Costa, Giosuè, Di Martino, Maria Teresa, Alcaro, Stefano, Tagliaferri, Pierosandro, and Tassone, Pierfrancesco

Abstract

Additional file 1: Supplementary Figures Figure S1. A Cartoon backbone representation of the superimposed DNA Binding Domains (DBD) of DNA Ligase I (green), III (orange) and IV (blue). B. Surface view of the DBD of ligase III (PDB ID 3L2P) . The positively charged groove targeted in the virtual screening is encircled by the dashed line. C. Surface view of the DBD of ligase I (PDB ID 1X9N). D. Surface view of the DBD of ligase IV (PDB ID 3W5O). Figure S2. A Immunoblot analysis of LIG4 expression in MM cell lines. GAPDH was used as loading control. B Representative FACS traces of Annexin V assay in AMO1 and H929 cells 4 days after RHM treatment (5 μM). C H929 cells were treated with vehicle or RHM (5 μM). 6 hours after either DMSO (NT) or Z-VAD-FMK were added to culture medium, at final concentration of 25 μM. Annexin V staining 4 days after treatment is shown. D Annexin V assay on U266 cells after 4 days of treatment with vehicle or RHM (5 μM). E Colony formation of AMO1 cells treated with vehicle or increasing dose of RHM. Light microscopy after 2 weeks is shown. F H&E stain of AMO1 and KMS26 cells after 5 days of treatment with vehicle or RHM (5 μM). Figure S3. A Cell cycle analysis in H929 cells treated with RHM (5 μM) with or without Caffeine (5 mM) for 48h. B ROS-Glo H2O2 assay performed in AMO1 and KMS26 cells 48h after treatment with vehicle or RHM (5 μM). C Relative percentage of CNV acquisition in AMO1 treated with RHM (2,5 μM) or vehicle, as evaluated by Affymetrix CytoScan HD Array analysis. Figure 4. A Cell viability of AMO1 and ABZB, treated with vehicle or increasing dose of Bortezomib for 48h. B Graphs of correlations between endogenous mRNA expression levels of LIG3 and MYC in MM patients with EFS

Published
2022
Full Text
View/download PDF

29. Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case-Control Study

Author

Arbitrio, Mariamena, Scionti, Francesca, Altomare, Emanuela, Di Martino, Maria Teresa, Agapito, Giuseppe, Galeano, Teresa, Staropoli, Nicoletta, Iuliano, Eleonora, Grillone, Francesco, Fabiani, Fernanda, Caracciolo, Daniele, Cannataro, Mario, Arpino, Grazia, Santini, Daniele, Tassone, Pierfrancesco, Tagliaferri, Pierosandro, Arbitrio, Mariamena, Scionti, Francesca, Altomare, Emanuela, Di Martino, Maria Teresa, Agapito, Giuseppe, Galeano, Teresa, Staropoli, Nicoletta, Iuliano, Eleonora, Grillone, Francesco, Fabiani, Fernanda, Caracciolo, Daniele, Cannataro, Mario, Arpino, Grazia, Santini, Daniele, Tassone, Pierfrancesco, and Tagliaferri, Pierosandro

Subjects
Paclitaxel, Prognosi, Receptors, Cytoplasmic and Nuclear, Peripheral Nervous System Diseases, Docetaxel, Middle Aged, Polymorphism, Single Nucleotide, Biomarkers, Pharmacological, Pharmacogenomic Testing, Antineoplastic Agent, Outcome Assessment, Health Care, Female, Glucuronosyltransferase, Case-Control Studie, Constitutive Androstane Receptor, Breast Neoplasm, Human
Abstract

Taxane-related peripheral neuropathy (TrPN) is a dose-limiting toxicity with important interindividual variability. Genetic polymorphisms in absorption, distribution, metabolism, and excretion (ADME) genes may account for variability in drug efficacy and/or toxicity. By the use of Affymetrix drug-metabolizing enzyme and transporter microarray platform, in a retrospective case-control study, the correlation between ADME polymorphic variants and grades≥2-3-TrPN was investigated. In a breast cancer (BC) training set, five single-nucleotide polymorphisms in NR1I3 and UDP-glucuronosyltransferase (UGT)2B7 genes were correlated to grades≥2-3-TrPN protection. By receiver operating characteristic curves, the grades≥2-3-TrPN-related candidate biomarkers in an independent series of 54 patients with BC (17 cases and 37 controls) were validated. NR1I3 was correlated to paclitaxel-TrPN and UGT2B7 to docetaxel-TrPN. Moreover, a genetic signature of prognostic relevance for BC outcome was found. Our findings might have potential relevance for personalized management of patients with BC for prevention of treatment failure in ultrametabolizer genetic variants.

Published
2019

30. SAT-288 - Genetic biomarkers for sorafenib response in patients with hepatocellular carcinoma

Author

Augello, Giuseppa, Arbitrio, Mariamena, Giannitrapani, Lydia, Scionti, Francesca, Ciliberto, Domenico, Staropoli, Nicoletta, Agapito, Giuseppe, Tassone, Pierfrancesco, Tagliaferri, Pierosandro, Soresi, Maurizio, Seidita, Aurelio, Affronti, Marco, Bertino, Gaetano, Russello, Maurizio, Di Gaudio, Francesca, Ciriminna, Rosaria, Spinnato, Francesca, Verderame, Francesco, and Cervello, Melchiorre

Published
2023
Full Text
View/download PDF

32. Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade

Author

Correale, Pierpaolo, primary, Saladino, Rita Emilena, additional, Giannarelli, Diana, additional, Giannicola, Rocco, additional, Agostino, Rita, additional, Staropoli, Nicoletta, additional, Strangio, Alessandra, additional, Del Giudice, Teresa, additional, Nardone, Valerio, additional, Altomonte, Maria, additional, Pastina, Pierpaolo, additional, Tini, Paolo, additional, Falzea, Antonia Consuelo, additional, Imbesi, Natale, additional, Arcati, Valentina, additional, Romeo, Giuseppa, additional, Caracciolo, Daniele, additional, Luce, Amalia, additional, Caraglia, Michele, additional, Giordano, Antonio, additional, Pirtoli, Luigi, additional, Necas, Alois, additional, Amler, Evzen, additional, Barbieri, Vito, additional, Tassone, Pierfrancesco, additional, and Tagliaferri, Pierosandro, additional

Published
2020
Full Text
View/download PDF

33. Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study

Author

Arbitrio Mariamena (1), Scionti Francesca (2), Altomare Emanuela (2), Di Martino Maria Teresa (2), Agapito Giuseppe (3), Galeano Teresa (2), Staropoli Nicoletta (4), Iuliano Eleonora(2), Grillone rancescaF (4), Fabiani Fernanda (5), Caracciolo Daniele (2), Cannataro Mario (3), Arpino Grazia (6), Santini Daniele (7), Tassone Pierfrancesco (2, and Tagliaferri Pierosandro (2

Subjects
DMET, ADME genes, Neurotoxicity, Single Nucleotide Polymorphism, Taxane, genomic signature
Abstract

Taxane-related peripheral neuropathy (TrPN) is a dose-limiting toxicity with important inter-individual variability. Genetic polymorphisms in ADME genes may account for variability in drug efficacy and/or toxicity. By the use of Affymetrix DMETTM microarray platform, in a retrospective case-control study, the correlation between ADME polymorphic variants and grade >=2-3 TrPN (G>=2-3 TrPN) was investigated. In a breast cancer (BC) training set, 5 SNPs in NR1I3 and UGT2B7genes were correlated to G>=2-3-TrPN protection. By ROC curves, the G>=2-3-TrPN-related candidate biomarkers in an independent series of 54 BC patients (17 cases and 37 controls) were validated. NR1I3 was correlated to Paclitaxel-TrPN and UGT2B7 to Docetaxel-TrPN. Moreover, a genetic signature of prognostic relevance for BC outcome was found. Our findings might have potential relevance for personalized management of BC patients for prevention of treatment failure in ultrametabolizer genetic variants.

Published
2019

34. Additional file 4: of Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma

Author

Cucè, Maria, Cantafio, Maria Gallo, Siciliano, Maria, Riillo, Caterina, Caracciolo, Daniele, Scionti, Francesca, Staropoli, Nicoletta, ZuccalĂ, Valeria, Maltese, Lorenza, Vito, Anna Di, Grillone, Katia, Barbieri, Vito, Mariamena Arbitrio, Martino, Maria Di, Rossi, Marco, Amodio, Nicola, Pierosandro Tagliaferri, Tassone, Pierfrancesco, and Botta, Cirino

Abstract

Figure S3. A GSEA results according to clueGO grouped by functions dependent on upregulated or downregulated genes. B Genes belonging to NER pathway resulted to be upregulated following trabectedin treatment in U266. Below, western blot to confirm DDB2 upregulation in 2 different cell lines. (PDF 974 kb)

Published
2019
Full Text
View/download PDF

35. Additional file 5: of Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma

Author

Cucè, Maria, Cantafio, Maria Gallo, Siciliano, Maria, Riillo, Caterina, Caracciolo, Daniele, Scionti, Francesca, Staropoli, Nicoletta, Zuccalà, Valeria, Maltese, Lorenza, Vito, Anna Di, Grillone, Katia, Barbieri, Vito, Mariamena Arbitrio, Martino, Maria Di, Rossi, Marco, Amodio, Nicola, Pierosandro Tagliaferri, Tassone, Pierfrancesco, and Botta, Cirino

Subjects
immune system diseases, hemic and lymphatic diseases
Abstract

Figure S4. A Western blot showing expression levels of anti-apoptotic proteins BCL-2 and MCL-1 in U266 and MM1S treated with different doses of trabectedin. B Representative dot plot of apoptosis induction and ROS production in U266 and MM1S cells after trabectedin-treatment respect to control, in presence or absence of ascorbic acid. C Western blot reporting protein expression of cell-cycle and DNA-damage regulators (p21, p-Chk2, RAD51 and gH2AX) in OPM2 cell line, after trabectedin treatment. D Representative immunohistochemistry showing gamma-h2ax foci (in brown) in the nuclei of U266 cells growth in matrigel-based spheroids, after 2.5 nM trabectedin treatment. E Surface expression of MICA/B and ULBP1 in U266, OPM2, RPMI8226 and MM1S cells treated with different concentrations of trabectedin for 48 h. All results represent the mean of at least 3 different individual experiments. F Dot plots report CD107a surface expression on NK-92 CI co-cultured with RPMI8226 untreated and exposed to trabectedin for 48 h. In the lowest part, histogram reporting the mean of the CD107a expression on NK92 co-cultured with U266 and OPM2 in 3 different experiments. G Gene expression levels of CRBN, CUL4 and DDB2 genes, all involved in the ubiquitination of IKZF1 protein, extracted from our gene expression profiling performed on U266 after 24 exposure to trabectedin. H Expression of pri-miR-17-92 in U266 and OPM2 in both cell lines after trabectedin treatment (2.5 Nm for U266 and 1 nM for OPM2). I Expression of miR-19b and miR-92a in U266 and OPM2 in absence or presence of trabectedin. These miRNAs do not belong to miR-17 family and were used as control for trabectedin specific activity. J Expression levels of mature miRNAs belonging to miR-17-92 cluster in stably pri-miR-17-92 overexpressing U266. K Representative dot plot of apoptotic activity of trabectedin treatment (2 .5nM) in 17–92-U266 cells respect to EV-U266 cells. *: p

Published
2019
Full Text
View/download PDF

36. Additional file 3: of Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma

Author

Cucè, Maria, Cantafio, Maria Gallo, Siciliano, Maria, Riillo, Caterina, Caracciolo, Daniele, Scionti, Francesca, Staropoli, Nicoletta, Zuccalà, Valeria, Maltese, Lorenza, Vito, Anna Di, Grillone, Katia, Barbieri, Vito, Mariamena Arbitrio, Martino, Maria Di, Rossi, Marco, Amodio, Nicola, Pierosandro Tagliaferri, Tassone, Pierfrancesco, and Botta, Cirino

Abstract

Figure S2. A Dot plots reporting pro-apoptotic activity of trabectedin after 24 h treatment in primary myeloma cells from three different patients. On the right, histogram reporting the % of viable cells. B Western blot images of a panel of 12 MM cell lines representing proteins belonging to NER pathway, which not exhibited a pattern associated with response to trabectedin. C Expression of the genes belonging to the NER pathway obtained by interrogating 2 different publicly available datasets (GSE68379 and GSE6205) including several MM cell lines used in our in vitro experiments. Cell lines segregate, in an unsupervised hierarchical clustering, accordingly to their response to trabectedin. D Dot plots of apoptotic activity of trabectedin in OPM2 and MM1S in presence (right) or absence (left) of monocytes, treated with 1 nM and 0.1 nM of the trabectedin, respectively in 3D model. E Unsupervised hierarchical clustering demonstrating that both duplicates achieved comparable results. In green cluster: trabectedin treated U266; in yellow cluster: control U266. F Shows the first 9 results of the gene set enrichment analysis according to their ranking. Importantly, 5/9 gene-sets affected involves DNA damages. Additionally, GSEA correctly identified that the whole transcriptome modulation may be dependent upon trabectedin treatment. *: p

Published
2019
Full Text
View/download PDF

37. Additional file 2: of Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma

Author

Cucè, Maria, Cantafio, Maria Gallo, Siciliano, Maria, Riillo, Caterina, Caracciolo, Daniele, Scionti, Francesca, Staropoli, Nicoletta, Zuccalà, Valeria, Maltese, Lorenza, Vito, Anna Di, Grillone, Katia, Barbieri, Vito, Mariamena Arbitrio, Martino, Maria Di, Rossi, Marco, Amodio, Nicola, Pierosandro Tagliaferri, Tassone, Pierfrancesco, and Botta, Cirino

Abstract

Figure S1. A Meta-analysis of 4 different GEP datasets of MM comparing the expression levels of genes belonging to different DNA-repair pathways (BER, MMR, HR, c-NHEJ, a-NHEJ, FA) in PCs from MM patients with PCs from healthy donors. B For each panel: on the left, forest plot showing the results of the multivariate COX regression analysis performed on all genes included in the specific DNA repair system. On the right, Kaplan-Meyer curve report results of prognostic system in which patients were divided into “low” and “high” risk group, according to the expression of genes identified by previous multivariate analysis. (PDF 605 kb)

Published
2019
Full Text
View/download PDF

39. GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up

Author

Caraglia, Michele, primary, Correale, Pierpaolo, additional, Giannicola, Rocco, additional, Staropoli, Nicoletta, additional, Botta, Cirino, additional, Pastina, Pierpaolo, additional, Nesci, Antonello, additional, Caporlingua, Nadia, additional, Francini, Edoardo, additional, Ridolfi, Laura, additional, Mini, Enrico, additional, Roviello, Giandomenico, additional, Ciliberto, Domenico, additional, Agostino, Rita Maria, additional, Strangio, Alessandra, additional, Azzarello, Domenico, additional, Nardone, Valerio, additional, Falzea, Antonella, additional, Cappabianca, Salvatore, additional, Bocchetti, Marco, additional, D'Arrigo, Graziella, additional, Tripepi, Giovanni, additional, Tassone, Pierfrancesco, additional, Addeo, Raffaele, additional, Giordano, Antonio, additional, Pirtoli, Luigi, additional, Francini, Guido, additional, and Tagliaferri, Pierosandro, additional

Published
2019
Full Text
View/download PDF

40. Evaluation of long term survival in pretreated metastatic colorectal cancer patients undergoing GOLFIG chemoimmunotherapy regimen.

Author

Correale, Pierpaolo, primary, Giannicola, Rocco, additional, Staropoli, NIcoletta, additional, Ciliberto, Domenico, additional, Azzarello, Domenico, additional, Tripepi, Giovanni, additional, Agostino, Rita Maria, additional, Strangio, Alessandra, additional, Altomonte, Maria, additional, Nesci, Antonio, additional, Francini, Guido, additional, Pastina, Pierpaolo, additional, Tassone, Pierfrancesco, additional, Pirtoli, Luigi, additional, Caporlingua, Nadia, additional, Falzea, Antonia Consuelo, additional, and Tagliaferri, Pierosandro, additional

Published
2019
Full Text
View/download PDF

41. Early blood rise in auto‑antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic‑non‑small cell lung cancer patients treated with PD‑1 immune‑check point blockade by nivolumab

Author

Giannicola, Rocco, primary, D'Arrigo, Graziella, additional, Botta, Cirino, additional, Agostino, Rita, additional, Del Medico, Pietro, additional, Falzea, Antonia, additional, Barbieri, Vito, additional, Staropoli, Nicoletta, additional, Del Giudice, Teresa, additional, Pastina, Pierpaolo, additional, Nardone, Valerio, additional, Monoriti, Marika, additional, Calabrese, Graziella, additional, Tripepi, Giovanni, additional, Pirtoli, Luigi, additional, Tassone, Pierfrancesco, additional, Tagliaferri, Pierosandro, additional, and Correale, Pierpaolo, additional

Published
2019
Full Text
View/download PDF

42. Polymorphic Variants inNR 1I3andUGT 2B7Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case‐Control Study

Author

Arbitrio, Mariamena, primary, Scionti, Francesca, additional, Altomare, Emanuela, additional, Di Martino, Maria Teresa, additional, Agapito, Giuseppe, additional, Galeano, Teresa, additional, Staropoli, Nicoletta, additional, Iuliano, Eleonora, additional, Grillone, Francesco, additional, Fabiani, Fernanda, additional, Caracciolo, Daniele, additional, Cannataro, Mario, additional, Arpino, Grazia, additional, Santini, Daniele, additional, Tassone, Pierfrancesco, additional, and Tagliaferri, Pierosandro, additional

Published
2019
Full Text
View/download PDF

43. Targeting a Specific Glycosylated Epitope of CD43 with a New Humanized Monoclonal Antibody for the Treatment of Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Author

Botta, Cirino, primary, Gaipa, Giuseppe, additional, Gallo Cantafio, Maria Eugenia, additional, Buracchi, Chiara, additional, Siciliano, Maria Anna, additional, Riillo, Caterina, additional, Grillone, Katia, additional, Gulino, Alessandro, additional, Cucè, Maria, additional, Staropoli, Nicoletta, additional, Ghelli Luserna Di Rora, Andrea, additional, Tuccillo, Franca Maria, additional, Di Martino, Maria Teresa, additional, Tripodo, Claudio, additional, Rossi, Marco, additional, Martinelli, Giovanni, additional, Biondi, Andrea, additional, Tagliaferri, Pierosandro, additional, and Tassone, Pierfrancesco, additional

Published
2018
Full Text
View/download PDF

44. Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine

Author

Correale, Pierpaolo, primary, Botta, Cirino, additional, Staropoli, Nicoletta, additional, Nardone, Valerio, additional, Pastina, Pierpaolo, additional, Ulivieri, Cristina, additional, Gandolfo, Claudia, additional, Baldari, Tatiana Cosima, additional, Lazzi, Stefano, additional, Ciliberto, Domenico, additional, Giannicola, Rocco, additional, Fioravanti, Antonella, additional, Giordano, Antonio, additional, Zappavigna, Silvia, additional, Caraglia, Michele, additional, Tassone, Pierfrancesco, additional, Pirtoli, Luigi, additional, Cusi, Maria Grazia, additional, and Tagliaferri, Pierosandro, additional

Published
2018
Full Text
View/download PDF

48. Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation

Author

Staropoli, Nicoletta, primary, Ciliberto, Domenico, additional, Chiellino, Silvia, additional, Caglioti, Francesca, additional, Del Giudice, Teresa, additional, Gualtieri, Simona, additional, Salvino, Angela, additional, Strangio, Alessandra, additional, Botta, Cirino, additional, Pignata, Sandro, additional, Tassone, Pierfrancesco, additional, and Tagliaferri, Pierosandro, additional

Published
2016
Full Text
View/download PDF

49. Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients

Author

Mignogna, Chiara, primary, Staropoli, Nicoletta, additional, Botta, Cirino, additional, De Marco, Carmela, additional, Rizzuto, Antonia, additional, Morelli, Michele, additional, Di Cello, Annalisa, additional, Franco, Renato, additional, Camastra, Caterina, additional, Presta, Ivan, additional, Malara, Natalia, additional, Salvino, Angela, additional, Tassone, Pierfrancesco, additional, Tagliaferri, Pierosandro, additional, Barni, Tullio, additional, Donato, Giuseppe, additional, and Di Vito, Anna, additional

Published
2016
Full Text
View/download PDF

50. Nanoparticle Albumin Bound Paclitaxel in the Treatment of Human Cancer: Nanodelivery Reaches Prime-Time?

Author

Cucinotto, Iole, Fiorillo, Lucia, Gualtieri, Simona, Arbitrio, Mariamena, Ciliberto, Domenico, Staropoli, Nicoletta, Grimaldi, Anna, Luce, Amalia, Tassone, Pierfrancesco, Caraglia, Michele, and Tagliaferri, Pierosandro

Subjects
Article Subject
Abstract

Nanoparticle albumin bound paclitaxel (nab-paclitaxel) represents the first nanotechnology-based drug in cancer treatment. We discuss the development of this innovative compound and report the recent changing-practice results in breast and pancreatic cancer. A ground-breaking finding is the demonstration that nab-paclitaxel can not only enhance the activity and reduce the toxicity of chromophore-diluted compound, but also exert activity in diseases considered refractory to taxane-based treatment. This is the first clinical demonstration of major activity of nanotechnologically modified drugs in the treatment of human neoplasms.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results